# Kiora Pharmaceuticals Inc: Form 10-Q for the period ended Sep 30, 2017

- Company: [Kiora Pharmaceuticals Inc](/companies/kprx.md) (CIK 1372514)
- Form: 10-Q
- Filed: 2017-11-14
- Accepted by EDGAR: Nov 14, 2017, 08:31 ET
- Period: 2017-09-30
- Accession: 0001144204-17-058607
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1372514/000114420417058607/tv478795_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1372514/000114420417058607/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2017-07-01 to 2017-09-30 | $3.2m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2017-01-01 to 2017-09-30 | $7.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2017-07-01 to 2017-09-30 | −$4.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2017-01-01 to 2017-09-30 | −$10.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2017-07-01 to 2017-09-30 | $304 | us-gaap:InterestExpense |
| Interest expense | 9 months, 2017-01-01 to 2017-09-30 | $912 | us-gaap:InterestExpense |
| Diluted EPS | 3 months, 2017-07-01 to 2017-09-30 | −$0.24 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2017-01-01 to 2017-09-30 | −$0.78 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2017-01-01 to 2017-09-30 | −$5.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2017-09-30 | $9.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-09-30 | $10.2m | us-gaap:AssetsCurrent |
| Total assets | at 2017-09-30 | $16.1m | us-gaap:Assets |
| Current liabilities | at 2017-09-30 | $12.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2017-09-30 | $15.4m | us-gaap:Liabilities |
| Shareholders' equity | at 2017-09-30 | $679.4k | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1372514/000114420417058607/tv478795_10q.htm

Filed Nov 14, 2017.
Source: SEC EDGAR, the filing index for accession 0001144204-17-058607. Last ingested by Listed: Nov 12, 2026, 17:43 ET. No prices; not investment advice.
